Download PDF
Pneumologie
DOI: 10.1055/a-2624-3671
Übersicht

Palliative Aspekte bei interstitiellen Lungenerkrankungen (ILD)

Palliative aspects in interstitial lung disease (ILD)
Michael Westhoff
1   Pneumology, Lungenklinik Hemer, Hemer, Deutschland (Ringgold ID: RIN14989)
2   Private University Witten/Herdecke, Witten, Deutschland (Ringgold ID: RIN12263)
,
Sandra Delis
3   Klinik für Pneumologie, Palliativmedizin und Geriatrie, Helios Klinikum Emil von Behring GmbH, Berlin, Deutschland (Ringgold ID: RIN14958)
› Author Affiliations
› Further Information
Also available at
   Permissions and Reprints

Zusammenfassung

Die interstitiellen Lungenerkrankungen (ILD) stellen eine Reihe heterogener pulmonaler Veränderungen dar, die durch Entzündung und Fibrose des Lungeninterstitiums gekennzeichnet sind. Sie stellen eine Krankheitsentität dar, die durch eine hohe Symptomlast und eine begrenzte Therapiemöglichkeit charakterisiert ist. Die Aspekte der palliativen Versorgungsstrategien bei interstitiellen Lungenerkrankungen gewinnen eine zunehmende Bedeutung. Hierzu wird die gegenwärtige Datenlage dargestellt und bewertet.

Abstract

Interstitial lung diseases (ILDs) encompass a range of heterogeneous pulmonary changes characterized by inflammation and fibrosis of the pulmonary interstitium. They represent a disease entity characterized by a high symptom burden and limited treatment options. The aspects of palliative care strategies for interstitial lung diseases are becoming increasingly important. The current data are presented and evaluated.

Schlüsselwörter

Palliativmedizin - Interstitielle Lungenerkrankungen - advanced care planning - Intensivmedizin

Keywords

palliative care - interstitial lung disease - advanced care planning - intensive care


Publication History

Received: 13 March 2025

Accepted after revision: 28 May 2025

Article published online:
12 June 2025

© 2025. Thieme. All rights reserved.

Georg Thieme Verlag KG
Oswald-Hesse-Straße 50, 70469 Stuttgart, Germany

 

  • Literatur

  • 1 Salciccioli JD, Marshall DC, Goodall R. et al. Interstitial lung disease incidence and mortality in the UK and the European Union: an observational study, 2001–2017. ERJ Open Res 2022; 8: 00058-2022
    CrossrefPubMedSearch in Google Scholar
  • 2 Raghu G, Collard HR, Egan JJ. et al. An official ATS/ERS/JRS/ALAT statement: idiopathic pulmonary fibrosis: evidence-based guidelines for diagnosis and management. Am J Respir Crit Care Med 2011; 183: 788-824
    CrossrefPubMedSearch in Google Scholar
  • 3 Aiello M, Bertorelli G, Bocchino M. et al. The earlier, the better: Impact of early diagnosis on clinical outcome in idiopathic pulmonary fibrosis. Pulm Pharmacol Ther 2017; 44: 7-15
    CrossrefPubMedSearch in Google Scholar
  • 4 Lancaster L, Bonella F, Inoue Y. et al. Idiopathic pulmonary fibrosis: Physician and patient perspectives on the pathway to care from symptom recognition to diagnosis and disease burden. Respirology 2022; 27: 66-75
    CrossrefPubMedSearch in Google Scholar
  • 5 Bramhill C, Langan D, Mulryan H. et al. A scoping review of the unmet needs of patients diagnosed with idiopathic pulmonary fibrosis (IPF). PLoS ONE 2024; 19: e0297832
    CrossrefPubMedSearch in Google Scholar
  • 6 van Manen MJ, Kreuter M, van den Blink B. et al. What patients with pulmonary fibrosis and their partners think: a live, educative survey in the Netherlands and Germany. ERJ Open Res 2017; 3: 00065-2016
    CrossrefPubMedSearch in Google Scholar
  • 7 Lyngaa T, Christiansen CF, Nielsen H. et al. Intensive care at the end of life in patients dying due to non-cancer chronic diseases versus cancer: a nationwide study in Denmark. Crit Care 2015; 19: 413
    CrossrefPubMedSearch in Google Scholar
  • 8 Chandel A, Pastre J, Valery S. et al. Derivation and validation of a simple multidimensional index incorporating exercise capacity parameters for survival prediction in idiopathic pulmonary fibrosis. Thorax 2023; 78: 368-375
    CrossrefPubMedSearch in Google Scholar
  • 9 Ahmadi Z, Wysham NG, Lundström S. et al. End-of-life care in oxygen-dependent ILD compared with lung cancer: a national population-based study. Thorax 2016; 71: 510-516
    CrossrefPubMedSearch in Google Scholar
  • 10 Zhao A, Gudmundsson E, Mogulkoc N. et al. Mortality surrogates in combined pulmonary fibrosis and emphysema. Eur Respir J 2024; 63: 2300127
    CrossrefPubMedSearch in Google Scholar
  • 11 Tomassetti S, Ravaglia C, Puglisi S. et al. Clinical implications of interstitial pneumonia with autoimmune features diagnostic criteria in idiopathic pulmonary fibrosis: A case control study. Front Med (Lausanne) 2023; 10: 1087485
    CrossrefPubMedSearch in Google Scholar
  • 12 Miyashita K, Kono M, Saito G. et al. Prognosis after acute exacerbation in patients with interstitial lung disease other than idiopathic pulmonary fibrosis. Clin Respir J 2021; 15: 336-344
    PubMedSearch in Google Scholar
  • 13 Kwon BS, Lee HY, Choe J. et al. Acute Respiratory Deterioration in Rheumatoid Arthritis-Associated Interstitial Lung Disease: A Single-Center Study. Chest 2022; 162: 136-144
    CrossrefPubMedSearch in Google Scholar
  • 14 Collard HR, Ryerson CJ, Corte TJ. et al. Acute Exacerbation of Idiopathic Pulmonary Fibrosis. An International Working Group Report. Am J Respir Crit Care Med 2016; 194: 265-275
    CrossrefPubMedSearch in Google Scholar
  • 15 Cottin V, Bonniaud P, Cadranel J. OrphaLung network. French practical guidelines for the diagnosis and management of idiopathic pulmonary fibrosis – 2021 update. Full-length version. Respir Med Res 2023; 83: 100948
    CrossrefPubMedSearch in Google Scholar
  • 16 Kim MJ, Yang J, Song JW. Acute exacerbation of progressive pulmonary fibrosis: incidence and outcomes. Respir Res 2024; 25: 415
    CrossrefPubMedSearch in Google Scholar
  • 17 Kondoh Y, Cottin V, Brown KK. Recent lessons learned in the management of acute exacerbation of idiopathic pulmonary fibrosis. Eur Respir Rev 2017; 26: 170050
    CrossrefPubMedSearch in Google Scholar
  • 18 WHO – neue Definition von Palliative Care (2002), abgerufen am 19.02.2025.
    PubMed
  • 19 Michels G, John S, Janssens U. et al. Palliativmedizinische Aspekte in der klinischen Akut- und Notfallmedizin sowie Intensivmedizin, Konsensuspapier der DGIIN, DGK, DGP, DGHO, DGfN, DGNI, DGG, DGAI, DGINA und DG Palliativmedizin. Pneumologie 2023; 77: 544-549
    Thieme ConnectPubMedSearch in Google Scholar
  • 20 Bramhill C, Langan D, Mulryan H. et al. A scoping review of the unmet needs of patients diagnosed with idiopathic pulmonary fibrosis (IPF). PLoS ONE 2024; 19: e0297832
    CrossrefPubMedSearch in Google Scholar
  • 21 In der Schmitten J, Nauck F, Marckmann G. et al. Behandlung im Voraus planen (Advance Care Planning): ein neues Konzept zur Realisierung wirksamer Patientenverfügungen. Z Palliativmed 2016; 17: 177-195
    Thieme ConnectPubMedSearch in Google Scholar
  • 22 Kim JW, Atkins C, Wilson AM. Barriers to specialist palliative care in interstitial lung disease: a systematic review. BMJ Support Palliat Care 2019; 9: 130-138
    CrossrefPubMedSearch in Google Scholar
  • 23 Philip J, Collins A, Smallwood N. et al. Referral criteria to palliative care for patients with respiratory disease: a systematic review. Eur Respir J 2021; 58: 2004307
    CrossrefPubMedSearch in Google Scholar
  • 24 Cassidy N, Fox L, Love M. et al. Fibrotic interstitial lung disease – palliative care needs: a World-Café qualitative study. BMJ Support Palliat Care 2024; 14: e2649-e2656
    CrossrefPubMedSearch in Google Scholar
  • 25 Smallwood N, Mann J, Guo H. et al. Patients With Fibrotic Interstitial Lung Disease Receive Supportive and Palliative Care Just Prior to Death. Am J Hosp Palliat Care 2021; 38: 154-160
    CrossrefPubMedSearch in Google Scholar
  • 26 Gersten RA, Seth B, Arellano L. et al. Pulmonary Fibrosis Foundation. Provider Perspectives on and Access to Palliative Care for Patients With Interstitial Lung Disease. Chest 2022; 162: 375-384
    CrossrefPubMedSearch in Google Scholar
  • 27 Koyauchi T, Suzuki Y, Sato K. et al. Quality of dying and death in patients with interstitial lung disease compared with lung cancer: an observational study. Thorax 2021; 76: 248-255
    CrossrefPubMedSearch in Google Scholar
  • 28 Rajala K, Lehto JT, Saarinen M. et al. End-of-life care of patients with idiopathic pulmonary fibrosis. BMC Palliat Care 2016; 15: 85
    CrossrefPubMedSearch in Google Scholar
  • 29 Tsim S, Chalmers GW. Discrepancy between symptom scoring and self-reported palliative care needs in a survey of interstitial lung disease patients. Palliat Med 2015; 29: 474-476
    CrossrefPubMedSearch in Google Scholar
  • 30 Bajwah S, Koffman J, Higginson IJ. et al. ‘I wish I knew more …’ the end-of-life planning and information needs for end-stage fibrotic interstitial lung disease: views of patients, carers and health professionals. BMJ Support Palliat Care 2013; 3: 84-90
    CrossrefPubMedSearch in Google Scholar
  • 31 Sørensen AR, Marsaa K, Prior TS. et al. Attitude and Barriers in Palliative Care and Advance Care Planning in Nonmalignant Chronic Lung Disease: Results From a Danish National Survey. J Palliat Care 2020; 35: 232-235
    CrossrefPubMedSearch in Google Scholar
  • 32 Maher TM, Swigris JJ, Kreuter M. et al. Identifying Barriers to Idiopathic Pulmonary Fibrosis Treatment: A Survey of Patient and Physician Views. Respiration 2018; 96: 514-524
    CrossrefPubMedSearch in Google Scholar
  • 33 Scheunemann LP, Ernecoff NC, Buddadhumaruk P. et al. Clinician-Family Communication About Patients' Values and Preferences in Intensive Care Units. JAMA Intern Med 2019; 179: 676-684
    CrossrefPubMedSearch in Google Scholar
  • 34 van Manen MJ, Kreuter M, van den Blink B. et al. What patients with pulmonary fibrosis and their partners think: a live, educative survey in the Netherlands and Germany. ERJ Open Res 2017; 3: 00065-2016
    CrossrefPubMedSearch in Google Scholar
  • 35 Wijsenbeek MS, Bonella F, Orsatti L. et al. Communicating with patients with idiopathic pulmonary fibrosis: can we do it better?. ERJ Open Res 2022; 8: 00422-2021
    CrossrefPubMedSearch in Google Scholar
  • 36 Barratt SL, Morales M, Speirs T. et al. Specialist palliative care, psychology, interstitial lung disease (ILD) multidisciplinary team meeting: a novel model to address palliative care needs. BMJ Open Respir Res 2018; 5: e000360
    CrossrefPubMedSearch in Google Scholar
  • 37 Koyauchi T, Fujisawa T, Miyashita M. et al. Prognostic Awareness and Knowledge of Acute Exacerbation in Patients Dying with Interstitial Lung Disease: A Nationwide Survey. Ann Am Thorac Soc 2025; 22: 395-402
    CrossrefPubMedSearch in Google Scholar
  • 38 Higginson IJ, Bausewein C, Reilly CC. et al. An integrated palliative and respiratory care service for patients with advanced disease and refractory breathlessness: a randomised controlled trial. Lancet Respir Med 2014; 2: 979-987
    CrossrefPubMedSearch in Google Scholar
  • 39 Archibald N, Bakal JA, Richman-Eisenstat J. et al. Early Integrated Palliative Care Bundle Impacts Location of Death in Interstitial Lung Disease: A Pilot Retrospective Study. Am J Hosp Palliat Care 2021; 38: 104-113
    CrossrefPubMedSearch in Google Scholar
  • 40 Kalluri M, Claveria F, Ainsley E. et al. Beyond Idiopathic Pulmonary Fibrosis Diagnosis: Multidisciplinary Care With an Early Integrated Palliative Approach Is Associated With a Decrease in Acute Care Utilization and Hospital Deaths. J Pain Symptom Manage 2018; 55: 420-426
    CrossrefPubMedSearch in Google Scholar
  • 41 Zou RH, Nouraie M, Chen X. et al. Assessing Patterns of Palliative Care Referral and Location of Death in Patients with Idiopathic Pulmonary Fibrosis: A Sixteen-Year Single-Center Retrospective Cohort Study. J Palliat Med 2019; 22: 538-544
    CrossrefPubMedSearch in Google Scholar
  • 42 Barnes H, McDonald J, Smallwood N. et al. Opioids for the palliation of refractory breathlessness in adults with advanced disease and terminal illness. Cochrane Database Syst Rev 2016; 3: CD011008
    PubMedSearch in Google Scholar
  • 43 Kronborg-White S, Andersen CU, Kohberg C. et al. Palliation of chronic breathlessness with morphine in patients with fibrotic interstitial lung disease – a randomised placebo-controlled trial. Respir Res 2020; 21: 195
    CrossrefPubMedSearch in Google Scholar
  • 44 Ferreira DH, Ekström M, Bajwah S. et al. Regular, low-dose, sustained-release morphine for persisting breathlessness in interstitial lung disease: a randomised, double-blind, placebo-controlled, crossover trial. Eur Respir J 2023; 62: 2300702
    CrossrefPubMedSearch in Google Scholar
  • 45 Takeyasu M, Miyamoto A, Kato D. et al. Continuous Intravenous Morphine Infusion for Severe Dyspnea in Terminally Ill Interstitial Pneumonia Patients. Intern Med 2016; 55: 725-729
    CrossrefPubMedSearch in Google Scholar
  • 46 Bajwah S, Davies JM, Tanash H. et al. Safety of benzodiazepines and opioids in interstitial lung disease: a national prospective study. Eur Respir J 2018; 52: 1801278
    CrossrefPubMedSearch in Google Scholar
  • 47 Birring SS, Kavanagh JE, Irwin RS. et al. Treatment of Interstitial Lung Disease Associated Cough: CHEST Guideline and Expert Panel Report. Chest 2018; 154: 904-917
    CrossrefPubMedSearch in Google Scholar
  • 48 Wu Z, Spencer LG, Banya W. et al. Morphine for treatment of cough in idiopathic pulmonary fibrosis (PACIFY COUGH): a prospective, multicentre, randomised, double-blind, placebo-controlled, two-way crossover trial. Lancet Respir Med 2024; 12: 273-280
    CrossrefPubMedSearch in Google Scholar
  • 49 Maher TM, Avram C, Bortey E. et al. Nalbuphine Tablets for Cough in Patients with Idiopathic Pulmonary Fibrosis. NEJM Evid 2023; 2: EVIDoa2300083
    CrossrefPubMedSearch in Google Scholar
  • 50 McGarvey LP, Birring SS, Morice AH. et al. Efficacy and safety of gefapixant, a P2X(3) receptor antagonist, in refractory chronic cough and unexplained chronic cough (COUGH-1 and COUGH-2): results from two double-blind, randomised, parallel-group, placebo-controlled, phase 3 trials. Lancet 2022; 399: 909-923
    CrossrefPubMedSearch in Google Scholar
  • 51 Martinez FJ, Afzal AS, Smith JA. et al. Treatment of persistent cough in subjects with idiopathic pulmonary fibrosis (IPF) with Gefapixant, a P2X3 antagonist, in a randomized placebo-controlled clinical trial. Pulm Ther 2021; 7: 471-486
    PubMedSearch in Google Scholar
  • 52 Hanada M, Kasawara KT, Mathur S. et al. Aerobic and breathing exercises improve dyspnea, exercise capacity and quality of life in idiopathic fibrosis patients: systematic review and meta-analysis. J Thorac Dis 2020; 12: 1041-1055
    CrossrefPubMedSearch in Google Scholar
  • 53 Patel AS, Watkin G, Willig B. et al. Improvement in health status following cough-suppression physiotherapy for patients with chronic cough. Chron Respir Dis 2011; 8: 253-258
    PubMedSearch in Google Scholar
  • 54 Lim CY, Khan SW, Alsibai T. et al. Examining Coughʼs Role and Relief Strategies in Interstitial Lung Disease. J Clin Med 2025; 14: 291
    CrossrefPubMedSearch in Google Scholar
  • 55 Guo H, Mann J, Goh N. et al. Investigation burden for patients with fibrotic interstitial lung disease at the end of life. Intern Med J 2020; 50: 748-752
    CrossrefPubMedSearch in Google Scholar
  • 56 Liang Z, Hoffman LA, Nouraie M. et al. Referral to Palliative Care Infrequent in Patients with Idiopathic Pulmonary Fibrosis Admitted to an Intensive Care Unit. J Palliat Med 2017; 20: 134-140
    CrossrefPubMedSearch in Google Scholar
  • 57 Brown CE, Engelberg RA, Nielsen EL. et al. Palliative Care for Patients Dying in the Intensive Care Unit with Chronic Lung Disease Compared with Metastatic Cancer. Ann Am Thorac Soc 2016; 13: 684-689
    CrossrefPubMedSearch in Google Scholar
  • 58 Akiyama N, Fujisawa T, Morita T. et al. End-of-life care for idiopathic pulmonary fibrosis patients with acute exacerbation. Respir Res 2022; 23: 294
    CrossrefPubMedSearch in Google Scholar
  • 59 Gifford AH. Noninvasive ventilation as a palliative measure. Curr Opin Support Palliat Care 2014; 8: 218-224
    CrossrefPubMedSearch in Google Scholar
  • 60 Perrin C, Jullien V, Duval Y. et al. Place de la ventilation non-invasive dans les soins palliatifs et en fin de vie [Noninvasive ventilation in palliative care and near the end of life]. Rev Mal Respir 2008; 25: 1227-1236
    CrossrefPubMedSearch in Google Scholar
  • 61 Vilaça M, Aragão I, Cardoso T. et al. The Role of Noninvasive Ventilation in Patients with “Do Not Intubate” Order in the Emergency Setting. PLoS One 2016; 11: e0149649
    CrossrefPubMedSearch in Google Scholar
  • 62 Zafrani L, Lemiale V, Lapidus N. et al. Acute respiratory failure in critically ill patients with interstitial lung disease. PLoS One 2014; 9: e104897
    CrossrefPubMedSearch in Google Scholar
  • 63 Luo Z, Yang L, Liu S. et al. Mechanical ventilation for acute respiratory failure due to idiopathic pulmonary fibrosis versus connective tissue disease-associated interstitial lung disease: Effectiveness and risk factors for death. Clin Respir J 2020; 14: 918-932
    CrossrefPubMedSearch in Google Scholar
  • 64 Kim SH, Lee DH, Yang B. et al. Which factors are helpful for the early determination of treatment level in patients with interstitial lung disease in the intensive care unit to minimize the suffering in their end of life? A retrospective study. Medicine (Baltimore) 2022; 101: e30524
    CrossrefPubMedSearch in Google Scholar
  • 65 Koyauchi T, Suzuki Y, Sato K. et al. Impact of end-of-life respiratory modalities on quality of dying and death and symptom relief in patients with interstitial lung disease: a multicenter descriptive cross-sectional study. Respir Res 2022; 23: 79
    CrossrefPubMedSearch in Google Scholar
  • 66 Krones T, Budilivschi A, Karzig I. et al. Advance care planning for the severely ill in the hospital: a randomized trial. BMJ Support Palliat Care 2019; 12: e411-423
    CrossrefPubMedSearch in Google Scholar
  • 67 Chai GT, Neo HY, Abisheganaden J. et al. Impact of Palliative Care in End-of-Life of Fibrotic Interstitial Lung Disease Patients. Am J Hosp Palliat Care 2022; 39: 1443-1451
    CrossrefPubMedSearch in Google Scholar